CD274 and non-small cell lung carcinoma: The impressive antitumor responses to checkpoint blockades of CTLA-4, PD-1, and PD-L1 have been seen in metastatic melanoma10, advanced NSCLC, renal cancer11, as well as in advanced bladder cancer12,13.